Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Esperion (ESPR) to $9 from $7 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s US Market Stagnation Overshadows Japanese Approval, Justifying Sell Rating
- Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
- Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost
- Esperion announces Otsuka received approval to market NEXLETOL in Japan
- Esperion bempedoic acid receives level 1a recommendation in ESC/EAS guidelines